StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research report report published on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Shares of Pulmatrix stock opened at $2.04 on Wednesday. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $3.14. The stock has a market capitalization of $7.45 million, a price-to-earnings ratio of -0.53 and a beta of 0.92. The company’s 50 day moving average price is $1.87 and its 200-day moving average price is $1.88.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter. Pulmatrix had a negative return on equity of 63.94% and a negative net margin of 193.49%. The firm had revenue of $2.20 million during the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- Health Care Stocks Explained: Why You Might Want to Invest
- MarketBeat Week in Review – 4/22 – 4/26
- Stock Splits, Do They Really Impact Investors?
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Start Investing in Real Estate
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
